| Year |
Citation |
Score |
| 2022 |
Luo TY, Shi Y, Wang G, Spaner DE. Enhanced IFN Sensing by Aggressive Chronic Lymphocytic Leukemia Cells. Journal of Immunology (Baltimore, Md. : 1950). PMID 36104109 DOI: 10.4049/jimmunol.2200199 |
0.334 |
|
| 2021 |
Spaner DE, Luo Y, Wang G, Gallagher J, Tsui H, Shi Y. Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial. Cancer Medicine. PMID 34791813 DOI: 10.1002/cam4.4378 |
0.303 |
|
| 2020 |
Xia M, Luo TY, Shi Y, Wang G, Tsui H, Harari D, Spaner DE. Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells. Journal of Immunology (Baltimore, Md. : 1950). PMID 33067379 DOI: 10.4049/jimmunol.2000478 |
0.334 |
|
| 2019 |
Shi Y, Wang G, Muhowski EM, McCaw L, Wang C, Bjarnason G, Woyach JA, Spaner DE. Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells. Leukemia. PMID 30696950 DOI: 10.1038/s41375-019-0381-4 |
0.359 |
|
| 2019 |
Whiting CC, Stock N, Messmer D, Olafson T, Metzger D, Enstrom A, McDevitt J, Spaner D, Prasit P, Panigrahy D, Laport G. Abstract 3606: Blockade of the PPARα metabolic checkpoint with TPST-1120 suppresses tumor growth and stimulates anti-tumor immunity Cancer Research. 79: 3606-3606. DOI: 10.1158/1538-7445.Sabcs18-3606 |
0.336 |
|
| 2018 |
Song J, Yuan C, Yang J, Liu T, Yao Y, Xiao X, Gajendran B, Xu D, Li YJ, Wang C, Liu W, Wen M, Spaner D, Filmus J, Zacksenhaus E, et al. Novel flavagline-like compounds with potent Fli-1 inhibitory activity suppress diverse types of leukemia. The Febs Journal. PMID 30387554 DOI: 10.1111/Febs.14690 |
0.335 |
|
| 2018 |
Reiman T, Savage KJ, Crump M, Cheung MC, MacDonald D, Buckstein R, Couban S, Piliotis E, Imrie K, Spaner D, Shivakumar S, Kuruvilla J, Villa D, Shepherd LE, Skamene T, et al. A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†. Leukemia & Lymphoma. 1-8. PMID 30301414 DOI: 10.1080/10428194.2018.1515937 |
0.304 |
|
| 2018 |
Chen CI, Paul H, Snitzler S, Kakar S, Le LW, Wei EN, Lau A, Johnston JB, Gibson SB, Queau M, Spaner D, Croucher D, Sherry B, Trudel S. A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL). Leukemia & Lymphoma. 1-10. PMID 30277089 DOI: 10.1080/10428194.2018.1508669 |
0.358 |
|
| 2018 |
Zhu F, Khatri I, Spaner D, Gorczynski RM. An autologous tumor vaccine for CLL. Leukemia Research. 68: 40-47. PMID 29525600 DOI: 10.1016/j.leukres.2018.03.002 |
0.316 |
|
| 2018 |
Smyth L, Buckstein R, Pennell N, Weerasinghe R, Cheung MC, Imrie K, Spaner D, Piliotis E, Chodirker L, Reis M, Ghorab Z, Zhang L, Boudreau V, Miliken A, Berinstein N. Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-α induces prolonged clinical and molecular remissions in patients with follicular lymphoma. British Journal of Haematology. PMID 29380359 DOI: 10.1111/Bjh.15118 |
0.364 |
|
| 2017 |
Sun L, Shi Y, Wang G, Wang X, Zeng S, Dunn SE, Fairn GD, Li YJ, Spaner DE. PPAR-delta modulates membrane cholesterol and cytokine-signaling in malignant B cells. Leukemia. PMID 28555083 DOI: 10.1038/leu.2017.162 |
0.309 |
|
| 2017 |
Li YJ, Sun L, Shi Y, Wang G, Wang X, Dunn S, Iorio C, Screaton RA, Spaner DE. PPAR-delta promotes survival of chronic lymphocytic leukemia cells in energetically unfavorable conditions. Leukemia. PMID 28050012 DOI: 10.1038/leu.2016.395 |
0.312 |
|
| 2017 |
Smyth L, Buckstein R, Nancy P, Weerasinghe R, Cheung M, Piliotis E, Imrie K, Spaner D, Reis MD, Chodirker L, Ghorab Z, ruth,nancy MV, Boudreau A, Berinstein N. Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α Blood. 130: 4069-4069. DOI: 10.1182/Blood.V130.Suppl_1.4069.4069 |
0.308 |
|
| 2016 |
McCaw L, Shi Y, Wang G, Li YJ, Spaner DE. Low Density Lipoproteins Amplify Cytokine-signaling in Chronic Lymphocytic Leukemia Cells. Ebiomedicine. PMID 27932296 DOI: 10.1016/j.ebiom.2016.11.033 |
0.319 |
|
| 2016 |
Reiman T, Savage KJ, Crump M, Cheung M, MacDonald DA, Buckstein R, Couban S, Piliotis E, Imrie KR, Spaner D, Shivakumar S, Kuruvilla J, Villa D, Shepherd LE, Skamene T, et al. A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15 Blood. 128: 4162-4162. DOI: 10.1182/Blood.V128.22.4162.4162 |
0.328 |
|
| 2015 |
Messmer D, Jacintho J, Lorrain K, Stebbins K, Bravo Y, Stock N, Cabrera G, Correa L, Chen A, Chiorazzi N, Yan XJ, Spaner D, Prasit P, Lorrain D. A selective novel Peroxisome-proliferator-activated receptor alpha (PPARα) antagonist induces apoptosis and inhibits proliferation of CLL cells in vitro and in vivo. Molecular Medicine (Cambridge, Mass.). PMID 26070013 DOI: 10.2119/molmed.2015.00139 |
0.314 |
|
| 2015 |
Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, ... ... Spaner DE, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 540-9. PMID 25154820 DOI: 10.1200/Jco.2014.56.2025 |
0.303 |
|
| 2014 |
Masoodi M, Lee E, Eiden M, Bahlo A, Shi Y, Ceddia RB, Baccei C, Prasit P, Spaner DE. A role for oleoylethanolamide in chronic lymphocytic leukemia Leukemia. 28: 1381-1387. PMID 24413323 DOI: 10.1038/leu.2014.10 |
0.309 |
|
| 2014 |
Gladstone DE, Andre M, Zaucha JM, Assouline SE, Bellam N, Cascavilla N, Jourdan E, Panwalkar AW, Patti C, Schulte C, Zaja F, Goswami T, Elgeioushi N, Spaner D. Phase 2 open-label study of MEDI-551 and bendamustine versus rituximab and bendamustine in adults with relapsed or refractory CLL. Journal of Clinical Oncology. 32: 3028-3028. DOI: 10.1200/Jco.2014.32.15_Suppl.3028 |
0.332 |
|
| 2013 |
Twito T, Chen Z, Khatri I, Wong K, Spaner D, Gorczynski R. Ectodomain shedding of CD200 from the B-CLL cell surface is regulated by ADAM28 expression. Leukemia Research. 37: 816-21. PMID 23643150 DOI: 10.1016/J.Leukres.2013.04.014 |
0.345 |
|
| 2013 |
Tomic J, McCaw L, Li Y, Hough MR, Ben-David Y, Moffat J, Spaner DE. Resveratrol has anti-leukemic activity associated with decreased O-GlcNAcylated proteins. Experimental Hematology. 41: 675-86. PMID 23597602 DOI: 10.1016/J.Exphem.2013.04.004 |
0.591 |
|
| 2013 |
Zhang L, Bridle BW, Chen L, Pol J, Spaner D, Boudreau JE, Rosen A, Bassett JD, Lichty BD, Bramson JL, Wan Y. Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses. Blood. 121: 2432-9. PMID 23325836 DOI: 10.1182/Blood-2012-06-438481 |
0.42 |
|
| 2013 |
Kochenderfer JN, Dudley ME, Kassim SH, Carpenter RO, Yang JC, Phan GQ, Hughes MS, Sherry RM, Feldman S, Spaner D, Nathan DN, Morton KE, Toomey MA, Rosenberg SA. Effective Treatment Of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma With Autologous T Cells Genetically-Engineered To Express An Anti-CD19 Chimeric Antigen Receptor Blood. 122: 168-168. DOI: 10.1182/Blood.V122.21.168.168 |
0.456 |
|
| 2012 |
Spaner DE, Lee E, Shi Y, Wen F, Li Y, Tung S, McCaw L, Wong K, Gary-Gouy H, Dalloul A, Ceddia R, Gorzcynski R. PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia. Leukemia. 27: 1090-9. PMID 23160450 DOI: 10.1038/leu.2012.329 |
0.355 |
|
| 2012 |
Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 119: 2709-20. PMID 22160384 DOI: 10.1182/blood-2011-10-384388 |
0.319 |
|
| 2012 |
Messmer D, Lorrain K, Bravo Y, Stock N, Bundey R, Correa L, Poon MM, Stebbins K, Cabrera G, Chen A, Jacintho J, Spaner D, Prasit P, Lorrain D. Inhibition of Fatty Acid Oxidation Leads to Apoptosis of Resting and Proliferating Chronic Lymphocytic Leukemia Cells in Vitro Blood. 120: 3879-3879. DOI: 10.1182/Blood.V120.21.3879.3879 |
0.444 |
|
| 2011 |
Tomic J, Lichty B, Spaner DE. Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. Blood. 117: 2668-80. PMID 21205928 DOI: 10.1182/Blood-2010-05-285999 |
0.625 |
|
| 2011 |
Chen CI, Bergsagel PL, Paul H, Xu W, Lau A, Dave N, Kukreti V, Wei E, Leung-Hagesteijn C, Li ZH, Brandwein J, Pantoja M, Johnston J, Gibson S, Hernandez T, ... Spaner D, et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1175-81. PMID 21189385 DOI: 10.1200/Jco.2010.29.8133 |
0.365 |
|
| 2011 |
Kochenderfer JN, Dudley ME, Feldman S, Wilson WH, Spaner D, Devillier L, Carpenter R, Nathan DN, Maric I, Morgan RA, Rosenberg SA. B-Cell Depletion, Remissions of Malignancy, and Cytokine-Associated Toxicity in a Clinical Trial of T Cells Genetically-Engineered to Express An Anti-CD19 Chimeric Antigen Receptor Blood. 118: 167-167. DOI: 10.1182/Blood.V118.21.167.167 |
0.467 |
|
| 2011 |
Spaner D, Bahlo A. B lymphocytes in cancer immunology Experimental and Applied Immunotherapy. 37-57. DOI: 10.1007/978-1-60761-980-2_2 |
0.324 |
|
| 2010 |
Shi Y, Tomic J, Wen F, Shaha S, Bahlo A, Harrison R, Dennis JW, Williams R, Gross BJ, Walker S, Zuccolo J, Deans JP, Hart GW, Spaner DE. Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia. Leukemia. 24: 1588-98. PMID 20668475 DOI: 10.1038/Leu.2010.152 |
0.612 |
|
| 2009 |
Shaha SP, Tomic J, Shi Y, Pham T, Mero P, White D, He L, Baryza JL, Wender PA, Booth JW, Spaner DE. Prolonging microtubule dysruption enhances the immunogenicity of chronic lymphocytic leukaemia cells. Clinical and Experimental Immunology. 158: 186-98. PMID 19737143 DOI: 10.1111/J.1365-2249.2009.04003.X |
0.65 |
|
| 2009 |
Hammond CM, Shi Y, White D, Cervi D, Tomic J, Spaner DE. The B-cell calcium sensor predicts progression of chronic lymphocytic leukemia. Leukemia. 23: 426-9. PMID 19078991 DOI: 10.1038/Leu.2008.351 |
0.579 |
|
| 2008 |
Pennell N, Cheung M, Hicks LK, Buckstein R, Imrie KR, Piliotis E, Spaner D, Ghorab Z, Reis MD, Milliken V, Boudreau A, Berinstein N. Hypogammaglobulinemia Following Rituximab and High-Dose Therapy and Autologous Stem-Cell Transplant: Incidence and Predictors of Prolonged Immunoglobulin Deficiencies Blood. 112: 4351-4351. DOI: 10.1182/Blood.V112.11.4351.4351 |
0.371 |
|
| 2007 |
Hammond CM, White D, Tomic J, Shi Y, Spaner DE. Extracellular calcium sensing promotes human B-cell activation and function. Blood. 110: 3985-95. PMID 17724142 DOI: 10.1182/Blood-2007-05-088468 |
0.604 |
|
| 2007 |
Shi Y, White D, He L, Miller RL, Spaner DE. Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Research. 67: 1823-31. PMID 17308125 DOI: 10.1158/0008-5472.CAN-06-2381 |
0.359 |
|
| 2006 |
Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study Journal of Clinical Oncology. 24: 5343-5349. PMID 17088571 DOI: 10.1200/Jco.2005.05.0401 |
0.38 |
|
| 2006 |
Tomic J, White D, Shi Y, Mena J, Hammond C, He L, Miller RL, Spaner DE. Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. Journal of Immunology (Baltimore, Md. : 1950). 176: 3830-9. PMID 16517754 DOI: 10.4049/Jimmunol.176.6.3830 |
0.633 |
|
| 2006 |
Spaner DE, Shi Y, White D, Mena J, Hammond C, Tomic J, He L, Tomai MA, Miller RL, Booth J, Radvanyi L. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia. 20: 286-95. PMID 16341037 DOI: 10.1038/Sj.Leu.2404061 |
0.65 |
|
| 2006 |
Miller K, Czuczman MS, Dimiceli L, Padmanabhan S, Lawrence D, Bernstein Z, Takeshita K, Spaner D, Byrne C, Crystal C, Chanan-Khan AA. Lenalidomide (L) induces high response rates with molecular remission in patients (pts) with relapsed (rel) or refractory (ref) chronic lymphocytic leukemia (CLL) Journal of Clinical Oncology. 24: 6517-6517. DOI: 10.1200/Jco.2006.24.18_Suppl.6517 |
0.347 |
|
| 2006 |
Chanan-Khan AA, Miller KC, Musial L, Padmanabhan S, Lawrence D, Bernstein ZP, Takeshita K, Spaner D, Byrne C, Chrystal C, Czuczman MS. Clinical Efficacy of Lenalidomide {Revlimid®} in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase II Clinical Trial. Blood. 108: 306-306. DOI: 10.1182/Blood.V108.11.306.306 |
0.324 |
|
| 2006 |
Hicks L, Connors JM, Mangel J, Buckstein R, Crump M, Leitch H, Imrie K, Nagy T, Boudreau A, Pennell N, Spaner D, Berinstein N. Autologous Stem-Cell Transplant with a Rituximab Purge and Maintenance vs. Standard Chemotherapy for Mantle Cell Lymphoma: Extended Follow-Up of a Matched Pair Analysis. Blood. 108: 3051-3051. DOI: 10.1182/Blood.V108.11.3051.3051 |
0.357 |
|
| 2005 |
Spaner DE, Miller RL, Mena J, Grossman L, Sorrenti V, Shi Y. Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. Leukemia & Lymphoma. 46: 935-9. PMID 16019542 DOI: 10.1080/10428190500054426 |
0.335 |
|
| 2005 |
Hammond C, Shi Y, Mena J, Tomic J, Cervi D, He L, Millar AE, Debenedette M, Schuh AC, Baryza JL, Wender PA, Radvanyi L, Spaner DE. Effect of serum and antioxidants on the immunogenicity of protein kinase C-activated chronic lymphocytic leukemia cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 28-39. PMID 15614042 DOI: 10.1097/00002371-200501000-00004 |
0.659 |
|
| 2004 |
Spaner DE, Hammond C, Mena J, Shi Y. Effect of IL-2R beta-binding cytokines on costimulatory properties of chronic lymphocytic leukaemia cells: implications for immunotherapy. British Journal of Haematology. 127: 531-42. PMID 15566356 DOI: 10.1111/j.1365-2141.2004.05240.x |
0.302 |
|
| 2004 |
Mangel J, Leitch HA, Connors JM, Buckstein R, Imrie K, Spaner D, Crump M, Pennell N, Boudreau A, Berinstein NL. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 15: 283-90. PMID 14760123 DOI: 10.1093/Annonc/Mdh069 |
0.379 |
|
| 2004 |
Pennell N, Woods A, Buckstein R, Imrie K, Spaner D, Reis M, Berinstein N. A Simplified Real-Time PCR Method for the Quantification of Minimal Residual Disease in Follicular Lymphoma. Blood. 104: 5203-5203. DOI: 10.1182/Blood.V104.11.5203.5203 |
0.337 |
|
| 2004 |
Buckstein R, Crump M, Shaked Y, Spaner D, Piliotis E, Imrie K, Nayar R, Foden C, Turner R, Taylor D, Man S, Baruchel S, Stempak D, Quirt I, Sturgeon J, et al. High Dose Celecoxib and Metronomic ‘Low-Dose’ Cyclophosphamide Is Effective Therapy in Patients with Relapsed and Refractory Aggressive Histology NHL. Blood. 104: 4622-4622. DOI: 10.1182/Blood.V104.11.4622.4622 |
0.35 |
|
| 2004 |
Hicks L, Shi Y, Mena J, Hammond C, Tomic Y, Tomai MA, Miller RL, Spaner DE. The Effect of a Toll Receptor-7 Agonist (S28690) on the Immunogenicity of Chronic Lymphocytic Leukemia Cells. Blood. 104: 3481-3481. DOI: 10.1182/Blood.V104.11.3481.3481 |
0.374 |
|
| 2003 |
Mangel J, Buckstein R, Imrie K, Spaner D, Franssen E, Pavlin P, Boudreau A, Pennell N, Combs D, Berinstein NL. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 14: 758-65. PMID 12702531 DOI: 10.1093/Annonc/Mdg201 |
0.367 |
|
| 2003 |
Kiss TL, Spaner D, Daly AS, Hasegawa WS, Lipton JH, Messner HA, Chang H. Complete remission of tumour with interleukin 2 therapy in a patient with non-Hodgkin's lymphoma post allogeneic bone marrow transplant associated with polyclonal T-cell bone marrow lymphocytosis. British Journal of Haematology. 120: 523-5. PMID 12580972 DOI: 10.1046/J.1365-2141.2003.04082.X |
0.341 |
|
| 2002 |
Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B, Deodhare S, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, et al. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Seminars in Oncology. 29: 56-69. PMID 28140093 DOI: 10.1053/Sonc.2002.30143 |
0.378 |
|
| 2002 |
Spaner D, Sheng-Tanner X, Schuh AC. Aberrant regulation of superantigen responses during T-cell reconstitution and graft-versus-host disease in immunodeficient mice. Blood. 100: 2216-24. PMID 12200388 DOI: 10.1182/Blood.V100.6.2216.H81802002216_2216_2224 |
0.406 |
|
| 2002 |
Gitelson E, Spaner D, Buckstein R, Franssen E, Hewitt K, Lim MS, Pennell N, Schultze JL, Berinstein NL. T-cell analysis in identical twins reveals an impaired anti-follicular lymphoma immune response in the patient but not in the healthy twin. British Journal of Haematology. 116: 122-7. PMID 11841404 DOI: 10.1046/J.1365-2141.2002.03240.X |
0.402 |
|
| 2002 |
Berinstein NL, Buckstein R, Imrie K, Spaner D, Mangel J, Tompkins K, Pennell N, Reis M, Pavlin P, Lima A, Couvadia A, Robinson J, Richardson P. Bcl-2 clearance: Optimising outcomes in follicular non-Hodgkin's lymphoma Bone Marrow Transplantation. 29. PMID 11840156 DOI: 10.1038/Sj.Bmt.1703297 |
0.428 |
|
| 2001 |
Raju K, Rabinovich BA, Radvanyi LG, Spaner D, Miller RG. A central role for IL-2 in fate determination of mature T cells - I: Role in determining the Th1/Th2 profile in primary T cell cultures International Immunology. 13: 1453-1459. PMID 11717186 DOI: 10.1093/Intimm/13.12.1453 |
0.348 |
|
| 2001 |
Gitelson E, Ghose A, Buckstein R, Imrie K, Lim MS, Reis M, Spaner D, Tartaglia J, Berinstein NL. ALVAC-mediated gene transfer is efficient in lymphoid malignancies of T-and early B-cell origin, but not in tumors arising from mature B-cells. Cancer Immunology, Immunotherapy : Cii. 50: 345-55. PMID 11676394 DOI: 10.1007/S002620100209 |
0.413 |
|
| 2000 |
Sheng-Tanner X, McKerlie C, Spaner D. Characterization of graft-versus-host disease in scid mice and prevention by physicochemical stressors Transplantation. 70: 1683-1693. PMID 11152097 DOI: 10.1097/00007890-200012270-00004 |
0.392 |
|
| 2000 |
Ghose A, Iakhnina E, Spaner D, Tartaglia J, Berinstein NL. Immunogenicity of whole-cell tumor preparations infected with the ALVAC viral vector. Human Gene Therapy. 11: 1289-301. PMID 10890739 DOI: 10.1089/10430340050032393 |
0.318 |
|
| 2000 |
Lakhnina E, Spaner D, Lorenzo MN, Buckstein R, Imrie K, Reis M, Berinstein NL. Tumor-reactive t-cell lines can be generated in the presence of large numbers of cll cells: Implications for vaccine development in CLL Blood. 96. |
0.317 |
|
| 1999 |
Spaner D, Sheng-Tanner X, Raju K, Rabinovich B, Messner H, Miller RG. Long-term persistence of IL-2-unresponsive allogeneic T cells in sublethally irradiated SCID mice International Immunology. 11: 1601-1614. PMID 10508178 DOI: 10.1093/Intimm/11.10.1601 |
0.418 |
|
| 1998 |
Spaner D. Geographical considerations regarding donor leukocyte infusions for the treatment of relapsed hematological malignancies Cancer and Metastasis Reviews. 17: 249-257. PMID 9770122 DOI: 10.1023/A:1006079108766 |
0.36 |
|
| 1996 |
Spaner D. Association of human lymphocyte antigens with obstructive airways disease after bone marrow transplantation Canadian Respiratory Journal. 3: 41-46. DOI: 10.1155/1996/540635 |
0.31 |
|
| 1993 |
Spaner D, Migita K, Ochi A, Shannon J, Miller RG, Pereira P, Tonegawa S, Phillips RA. Gamma delta T cells differentiate into a functional but nonproliferative state during a normal immune response. Proceedings of the National Academy of Sciences of the United States of America. 90: 8415-9. PMID 8378313 |
0.349 |
|
| Show low-probability matches. |